Amiri R, Farrokhnia M, Mousavi Mehdiabadi F. Disseminated cutaneous leishmaniasis in a kidney transplant recipient.
Clin Case Rep 2023;
11:e7549. [PMID:
37323282 PMCID:
PMC10264955 DOI:
10.1002/ccr3.7549]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 05/18/2023] [Accepted: 06/02/2023] [Indexed: 06/17/2023] Open
Abstract
Key Clinical Message
In this case of disseminated cutaneous leishmaniasis in our immunosuppressive patient who was a refractor to treatment with intra-lesion Glucantime® and systemic L-AmB, considering the good clinical response to oral miltefosine, this drug might be the best treatment option.
Abstract
Diagnosis and treatment of leishmaniasis are challenging in immunosuppressed patients. Here, we report a 46-year-old male renal transplant recipient with disseminated cutaneous leishmaniasis presenting with multiple lesions on the face and upper extremities 15 years after transplant with a challenging course of treatment with meglumine antimoniate, liposomal amphotericin B, and miltefosine.
Collapse